Chris Schott
Stock Analyst at JP Morgan
(3.49)
# 763
Out of 4,814 analysts
126
Total ratings
53.01%
Success rate
1.54%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,100 → $1,000 | $563.16 | +77.57% | 6 | Mar 31, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $130 | $104.53 | +24.37% | 5 | Mar 27, 2025 | |
| AMRX Amneal Pharmaceuticals | Upgrades: Overweight | $9 → $12 | $7.36 | +63.04% | 2 | Feb 24, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $200 | $173.00 | +15.61% | 2 | Nov 13, 2024 | |
| BIIB Biogen | Maintains: Neutral | $220 → $210 | $118.61 | +77.05% | 3 | Nov 4, 2024 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Neutral | $16 → $18 | $13.64 | +32.01% | 15 | Oct 21, 2024 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $630 → $575 | $411.55 | +39.72% | 7 | Oct 11, 2024 | |
| ZTS Zoetis | Maintains: Overweight | $225 → $230 | $148.66 | +54.72% | 2 | Oct 11, 2024 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,050 → $1,100 | $839.90 | +30.97% | 20 | Sep 13, 2024 | |
| OGN Organon & Co. | Downgrades: Underweight | $18 → $20 | $11.12 | +79.86% | 2 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $41 | $25.37 | +61.61% | 11 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $32.51 | +29.19% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $277.29 | -2.63% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $22.15 | +53.53% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $77.98 | +60.30% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $7.39 | +89.45% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.12 | +882.14% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $20 | $8.44 | +136.97% | 3 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.60 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $49.23 | +58.46% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $3.45 | +27,436.23% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.00 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $24.68 | +102.59% | 3 | Nov 2, 2018 |
Regeneron Pharmaceuticals
Mar 31, 2025
Maintains: Overweight
Price Target: $1,100 → $1,000
Current: $563.16
Upside: +77.57%
Gilead Sciences
Mar 27, 2025
Maintains: Overweight
Price Target: $120 → $130
Current: $104.53
Upside: +24.37%
Amneal Pharmaceuticals
Feb 24, 2025
Upgrades: Overweight
Price Target: $9 → $12
Current: $7.36
Upside: +63.04%
AbbVie
Nov 13, 2024
Maintains: Overweight
Price Target: $210 → $200
Current: $173.00
Upside: +15.61%
Biogen
Nov 4, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $118.61
Upside: +77.05%
Teva Pharmaceutical Industries
Oct 21, 2024
Maintains: Neutral
Price Target: $16 → $18
Current: $13.64
Upside: +32.01%
IDEXX Laboratories
Oct 11, 2024
Maintains: Overweight
Price Target: $630 → $575
Current: $411.55
Upside: +39.72%
Zoetis
Oct 11, 2024
Maintains: Overweight
Price Target: $225 → $230
Current: $148.66
Upside: +54.72%
Eli Lilly and Company
Sep 13, 2024
Maintains: Overweight
Price Target: $1,050 → $1,100
Current: $839.90
Upside: +30.97%
Organon & Co.
Sep 6, 2024
Downgrades: Underweight
Price Target: $18 → $20
Current: $11.12
Upside: +79.86%
Feb 28, 2024
Maintains: Overweight
Price Target: $48 → $41
Current: $25.37
Upside: +61.61%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $32.51
Upside: +29.19%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $277.29
Upside: -2.63%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $22.15
Upside: +53.53%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $77.98
Upside: +60.30%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $7.39
Upside: +89.45%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.12
Upside: +882.14%
Oct 17, 2022
Maintains: Neutral
Price Target: $24 → $20
Current: $8.44
Upside: +136.97%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $4.60
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $49.23
Upside: +58.46%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $3.45
Upside: +27,436.23%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $1.00
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $24.68
Upside: +102.59%